Protein kinase C, an elusive therapeutic target? (original) (raw)

• Castagna, M. et al. Direct activation of calcium-activated, phospholipid-dependent protein-kinase by tumor-promoting phorbo esters. J. Biol. Chem. 257, 7847–7851 (1982). This is the first study that suggested a pathological role for PKC in cancer and triggered active research in the scientific community.
  CAS PubMed Google Scholar
• Geraldes, P. & King, G. L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 106, 1319–1331 (2010).
  CAS PubMed PubMed Central Google Scholar
• Toton, E., Ignatowicz, E., Skrzeczkowska, K. & Rybczynska, M. Protein kinase Cɛ as a cancer marker and target for anticancer therapy. Pharmacol. Rep. 63, 19–29 (2011).
  CAS PubMed Google Scholar
• Inagaki, K., Churchill, E. & Mochly-Rosen, D. Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc. Res. 70, 222–230 (2006).
  CAS PubMed Google Scholar
• Ferreira, J. C., Brum, P. C. & Mochly-Rosen, D. βIIPKC and ɛPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J. Mol. Cell. Cardiol. 51, 479–484 (2011).
  CAS PubMed Google Scholar
• Zanin-Zhorov, A., Dustin, M. L. & Blazar, B. R. PKC-θ function at the immunological synapse: prospects for therapeutic targeting. Trends Immunol. 32, 358–363 (2011).
  CAS PubMed PubMed Central Google Scholar
• Burguillos, M. A. et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 472, 319–324 (2011).
  CAS PubMed Google Scholar
• Zhang, D., Anantharam, V., Kanthasamy, A. & Kanthasamy, A. G. Neuroprotective effect of protein kinase Cδ inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. 322, 913–922 (2007).
  CAS PubMed Google Scholar
• Garrido, J. L., Godoy, J. A., Alvarez, A., Bronfman, M. & Inestrosa, N. C. Protein kinase C inhibits amyloid β peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 16, 1982–1984 (2002).
  CAS PubMed Google Scholar
• Manji, H. K. & Lenox, R. H. The nature of bipolar disorder. J. Clin. Psychiatry 61 (Suppl. 13), 42–57 (2000).
  PubMed Google Scholar
• Zarate, C. A. & Manji, H. K. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23, 569–582 (2009).
  CAS PubMed PubMed Central Google Scholar
• Maioli, E. & Valacchi, G. Rottlerin: bases for a possible usage in psoriasis. Curr. Drug Metab. 11, 425–430 (2010).
  CAS PubMed Google Scholar
• Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002). This is a detailed analysis of kinase inhibitors of the ATP-binding site across the kinome, and it provides effective visual illustrations for the lack of specificity of the inhibitors for specific protein kinases.
  CAS PubMed Google Scholar
• Takai, Y., Kishimoto, A., Inoue, M. & Nishizuka, Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. 1. Purification and characterization of an active enzyme from bovine cerebellum. J. Biol. Chem. 252, 7603–7609 (1977). This is the first description of PKC activity by Nishizuka's laboratory.
  CAS PubMed Google Scholar
• Takai, Y., Kishimoto, A., Kikkawa, U., Mori, T. & Nishizuka, Y. Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid dependent protein-kinase system. Biochem. Biophys. Res. Commun. 91, 1218–1224 (1979).
  CAS PubMed Google Scholar
• Coussens, L. et al. Multiple, distinct forms of bovin and human protein-kinase-C suggest diversity in cellular signaling pathway. Science 233, 859–866 (1986).
  CAS PubMed Google Scholar
• Ono, Y. et al. The structure, expression, and properties of additional members of the protein kinase C family. J. Biol. Chem. 263, 6927–6932 (1988).
  CAS PubMed Google Scholar
• Ono, Y. et al. Expression and properties of two types of protein kinase C: alternative splicing from a single gene. Science 236, 1116–1120 (1987).
  CAS PubMed Google Scholar
• Parker, P. J. et al. The complete primary structure of protein-kinase C — the phorbol ester receptor. Science 233, 853–859 (1986).
  CAS PubMed Google Scholar
• Hirai, T. & Chida, K. Protein kinase Cζ (PKCζ): activation mechanisms and cellular functions. J. Biochem. 133, 1–7 (2003).
  CAS PubMed Google Scholar
• Suzuki, A., Akimoto, K. & Ohno, S. Protein kinase Cλ/ι (PKCλ/ι): a PKC isotype essential for the development of multicellular organisms. J. Biochem. 133, 9–16 (2003).
  CAS PubMed Google Scholar
• Steinberg, S. F. Structural basis of protein kinase C isoform function. Physiol. Rev. 88, 1341–1378 (2008).
  CAS PubMed Google Scholar
• Persaud, S. D., Hoang, V., Huang, J. & Basu, A. Involvement of proteolytic activation of PKCδ in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. Int. J. Oncol. 27, 149–154 (2005).
  CAS PubMed Google Scholar
• Newton, A. C. Protein kinase C: structure, function, and regulation. J. Biol. Chem. 270, 28495–28498 (1995). This is a review of the family of PKC isozymes.
  CAS PubMed Google Scholar
• Konishi, H. et al. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2 . Proc. Natl Acad. Sci. USA 94, 11233–11237 (1997).
  CAS PubMed PubMed Central Google Scholar
• Konishi, H. et al. Phosphorylation sites of protein kinase Cδ in H2O2-treated cells and its activation by tyrosine kinase in vitro. Proc. Natl Acad. Sci. USA 98, 6587–6592 (2001).
  CAS PubMed PubMed Central Google Scholar
• Mochly-Rosen, D. Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science 268, 247–251 (1995).
  CAS PubMed Google Scholar
• Chen, L. et al. Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and ɛPKC. Proc. Natl Acad. Sci. USA 98, 11114–11119 (2001). This paper provides the first evidence that the same PKC isozymes may have opposing roles.
  CAS PubMed PubMed Central Google Scholar
• Murriel, C. L. & Mochly-Rosen, D. Opposing roles of δ and ɛ PKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch. Biochem. Biophys. 420, 246–254 (2003).
  CAS PubMed Google Scholar
• Basu, A. & Pal, D. Two faces of protein kinase Cδ: the contrasting roles of PKCδ in cell survival and cell death. ScientificWorldJournal 10, 2272–2284 (2010).
  CAS PubMed PubMed Central Google Scholar
• Michie, A. M. & Nakagawa, R. The link between PKCα regulation and cellular transformation. Immunol. Lett. 96, 155–162 (2005).
  CAS PubMed Google Scholar
• Ishii, H. et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science 272, 728–731 (1996).
  CAS PubMed Google Scholar
• Simonis, G., Braun, M. U., Kirrstetter, M., Schon, S. P. & Strasser, R. H. Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-ɛ in the surviving myocardium early after infarction. J. Cardiovasc. Pharmacol. 41, 780–787 (2003).
  CAS PubMed Google Scholar
• Bowling, N. et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99, 384–391 (1999).
  CAS PubMed Google Scholar
• Palaniyandi, S. S., Sun, L., Ferreira, J. C. & Mochly-Rosen, D. Protein kinase C in heart failure: a therapeutic target? Cardiovasc. Res. 82, 229–239 (2009).
  CAS PubMed PubMed Central Google Scholar
• Koyanagi, T. et al. Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model. J. Mol. Cell. Cardiol. 43, 517–522 (2007).
  CAS PubMed Google Scholar
• Dempsey, E. C., Cool, C. D. & Littler, C. M. Lung disease and PKCs. Pharmacol. Res. 55, 545–559 (2007).
  CAS PubMed Google Scholar
• Li, J. & Gobe, G. Protein kinase C activation and its role in kidney disease. Nephrology 11, 428–434 (2006).
  CAS PubMed Google Scholar
• Tuttle, K. R. Protein kinase C-β inhibition for diabetic kidney disease. Diabetes Res. Clin. Pract. 82 (Suppl. 1), 70–74 (2008).
  Google Scholar
• Varin, M. M. et al. In Sjogren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase Cδ activation. Autoimmun. Rev. 11, 252–258 (2012).
  CAS PubMed Google Scholar
• Bright, R. & Mochly-Rosen, D. The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke 36, 2781–2790 (2005).
  CAS PubMed Google Scholar
• Sun, M.-K. & Alkon, D. L. Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics. Pharmacol. Therap. 127, 66–77 (2010).
  CAS Google Scholar
• Alkon, D. L., Sun, M. K. & Nelson, T. J. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol. Sci. 28, 51–60 (2007).
  CAS PubMed Google Scholar
• Sweitzer, S. M. et al. Protein kinase Cɛ and γ: involvement in formalin-induced nociception in neonatal rats. J. Pharmacol. Exp. Ther. 309, 616–625 (2004).
  CAS PubMed Google Scholar
• Ytrehus, K., Liu, Y. & Downey, J. M. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol. 266, H1145–H1152 (1994).
  CAS PubMed Google Scholar
• Brooks, G. & Hearse, D. J. Role of protein kinase C in ischemic preconditioning: player or spectator? Circ. Res. 79, 627–630 (1996).
  CAS PubMed Google Scholar
• Churchill, E. N., Murriel, C. L., Chen, C. H., Mochly-Rosen, D. & Szweda, L. I. Reperfusion-induced translocation of δPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation. Circ. Res. 97, 78–85 (2005).
  CAS PubMed Google Scholar
• Churchill, E. N., Ferreira, J. C., Brum, P. C., Szweda, L. I. & Mochly-Rosen, D. Ischaemic preconditioning improves proteasomal activity and increases the degradation of δPKC during reperfusion. Cardiovasc. Res. 85, 385–394 (2010).
  CAS PubMed Google Scholar
• Pratschke, J., Weiss, S., Neuhaus, P. & Pascher, A. Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation. Transpl. Int. 21, 512–522 (2008).
  PubMed Google Scholar
• Tanaka, M. et al. Suppression of graft coronary artery disease by a brief treatment with a selective ɛPKC activator and a δPKC inhibitor in murine cardiac allografts. Circulation 110 (Suppl. II), 194–199 (2004).
  Google Scholar
• Sarma, N. J., Tiriveedhi, V., Angaswamy, N. & Mohanakumar, T. Role of antibodies to self-antigens in chronic allograft rejection: potential mechanism and therapeutic implications. Hum. Immunol. 9 Jul 2012 [epub ahead of print].
• Inagaki, K., Hahn, H. S., Dorn, G. W. & Mochly-Rosen, D. Additive protection of the ischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and ɛ-protein kinase C activator. Circulation 108, 869–875 (2003).
  CAS PubMed Google Scholar
• Lee, M. R., Duan, W. & Tan, S. L. Protein kinase C isozymes as potential therapeutic targets in immune disorders. Expert Opin. Ther. Targets 12, 535–552 (2008).
  CAS PubMed Google Scholar
• Sledge, G. W. Jr & Gokmen-Polar, Y. Protein kinase C-β as a therapeutic target in breast cancer. Semin. Oncol. 33, S15–S18 (2006).
  CAS PubMed Google Scholar
• Kim, J., Koyanagi, T. & Mochly-Rosen, D. PKCδ activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells. Prostate 71, 946–954 (2011).
  CAS PubMed Google Scholar
• Bacher, N., Zisman, Y., Berent, E. & Livneh, E. Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin, and heart. Mol. Cell. Biol. 11, 126–133 (1991).
  CAS PubMed PubMed Central Google Scholar
• Krasnitsky, E. et al. PKCη is a novel prognostic marker in non-small cell lung cancer. Anticancer Res. 32, 1507–1513 (2012).
  PubMed Google Scholar
• Kim, K. M. et al. PKCθ expression in gastrointestinal stromal tumor. Mod. Pathol. 19, 1480–1486 (2006).
  CAS PubMed Google Scholar
• Nishikawa, T., Edelstein, D. & Brownlee, M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int. Suppl. 77, S26–S30 (2000).
  CAS PubMed Google Scholar
• Bezy, O. et al. PKCδ regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans. J. Clin. Invest. 121, 2504–2517 (2011).
  CAS PubMed PubMed Central Google Scholar
• Manji, H. K. et al. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J. Clin. Psychiatry 60 (Suppl. 2), 27–39; discussion 40–41, 113–116 (1999).
  PubMed Google Scholar
• DiazGranados, N. & Zarate, C. A. Jr. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr. Psychiatry Rep. 10, 510–519 (2008).
  PubMed PubMed Central Google Scholar
• Einat, H., Yuan, P., Szabo, S. T., Dogra, S. & Manji, H. K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55, 123–131 (2007).
  CAS PubMed Google Scholar
• Wang, H. Y., Markowitz, P., Levinson, D., Undie, A. S. & Friedman, E. Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J. Psychiatr. Res. 33, 171–179 (1999).
  CAS PubMed Google Scholar
• Wang, H. Y. & Friedman, E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol. Psychiatry 40, 568–575 (1996).
  CAS PubMed Google Scholar
• Sadeh, J. S. et al. Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch. Dermatol. 133, 747–750 (1997).
  CAS PubMed Google Scholar
• Nishino, N., Kitamura, N., Hashimoto, T. & Tanaka, C. Transmembrane signalling systems in the brain of patients with Parkinson's disease. Rev. Neurosci. 4, 213–222 (1993).
  CAS PubMed Google Scholar
• Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotech. 26, 127–132 (2008).
  CAS Google Scholar
• Sobhia, M. E., Grewal, B. K., Bhat, J., Rohit, S. & Punia, V. Protein kinase CβII in diabetic complications: survey of structural, biological and computational studies. Expert Opin. Ther. Targets 16, 325–344 (2012).
  CAS PubMed Google Scholar
• Wilkinson, S. E., Parker, P. J. & Nixon, J. S. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem. J. 294, 335–337 (1993).
  CAS PubMed PubMed Central Google Scholar
• Lee, K. W. et al. Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 68, 1916–1926 (2008).
  CAS PubMed Google Scholar
• Gschwendt, M. et al. Rottlerin, a novel protein-kinase inhibitor. Biochem. Biophys. Res. Commun. 199, 93–98 (1994).
  CAS PubMed Google Scholar
• Soltoff, S. P. Rottlerin: an inappropriate and ineffective inhibitor of PKCδ. Trends Pharmacol. Sci. 28, 453–458 (2007).
  CAS PubMed Google Scholar
• Zimmermann, J. et al. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch. Pharm. 329, 371–376 (1996).
  CAS Google Scholar
• Cole, D. C. et al. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase Cθ (PKCθ) inhibitors. J. Med. Chem. 51, 5958–5963 (2008).
  CAS PubMed Google Scholar
• Pande, V., Ramos, M. J. & Gago, F. The protein kinase inhibitor balanol: structure–activity relationships and structure-based computational studies. Anticancer Agents Med. Chem. 8, 638–645 (2008).
  CAS PubMed Google Scholar
• Noh, K. M., Hwang, J. Y., Shin, H. C. & Koh, J. Y. A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol. Dis. 7, 375–383 (2000).
  CAS PubMed Google Scholar
• Blumberg, P. M. In vitro studies on the mode of action of the phorbol esters, potent tumor promoters: part 1. Crit. Rev. Toxicol. 8, 153–197 (1980). This is one of the early studies that elucidated the pharmacology of phorbol esters.
  CAS PubMed Google Scholar
• Blumberg, P. M. et al. Mechanism of action of the phorbol ester tumor promoters: specific receptors for lipophilic ligands. Biochem. Pharmacol. 33, 933–940 (1984).
  CAS PubMed Google Scholar
• Marquez, V. E. et al. The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands. Pharmacol. Ther. 82, 251–261 (1999).
  CAS PubMed Google Scholar
• Garcia-Bermejo, M. L. et al. Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKCα. J. Biol. Chem. 277, 645–655 (2002).
  CAS PubMed Google Scholar
• Workman, P., Kaye, S. B. & Schwartsmann, G. Laboratory and phase I studies of new cancer drugs. Curr. Opin. Oncol. 4, 1065–1072 (1992).
  CAS PubMed Google Scholar
• Dowlati, A. et al. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin. Cancer Res. 9, 5929–5935 (2003).
  CAS PubMed Google Scholar
• Szallasi, Z. et al. Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol. Pharmacol. 46, 840–850 (1994).
  CAS PubMed Google Scholar
• Wender, P. A., Verma, V. A., Paxton, T. J. & Pillow, T. H. Function-oriented synthesis, step economy, and drug design. Accounts Chem. Res. 41, 40–49 (2008).
  CAS Google Scholar
• Shindo, M. et al. Toward the identification of selective modulators of protein kinase C (PKC) isozymes: establishment of a binding assay for PKC isozymes using synthetic C1 peptide receptors and identification of the critical residues involved in the phorbol ester binding. Bioorg. Med. Chem. 9, 2073–2081 (2001).
  CAS PubMed Google Scholar
• Wender, P. A. et al. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc. Natl Acad. Sci. USA 108, 6721–6726 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wender, P. A. et al. Inspirations from nature. New reactions, therapeutic leads, and drug delivery systems. Pure Appl. Chem. 75, 143–155 (2003).
  CAS Google Scholar
• Kraft, A. S., Anderson, W. B., Cooper, H. L. & Sando, J. J. Decrease in cytosolic calcium phospholipid-dependent protein-kinase activity following phorbol ester treatment of EL4 thymoma cells. J. Biol. Chem. 257, 3193–3196 (1982).
  Google Scholar
• Disatnik, M. H., Buraggi, G. & Mochly-Rosen, D. Localization of protein kinase C isozymes in cardiac myocytes. Exp. Cell Res. 210, 287–297 (1994).
  CAS PubMed Google Scholar
• Mochly-Rosen, D., Henrich, C. J., Cheever, L., Khaner, H. & Simpson, P. C. A protein kinase C isozyme is translocated to cytoskeletal elements on activation. Cell Regul. 1, 693–706 (1990).
  CAS PubMed PubMed Central Google Scholar
• Budas, G. R., Churchill, E. N., Disatnik, M. H., Sun, L. & Mochly-Rosen, D. Mitochondrial import of PKCɛ is mediated by HSP90: a role in cardioprotection from ischaemia and reperfusion injury. Cardiovasc. Res. 88, 83–92 (2010).
  CAS PubMed PubMed Central Google Scholar
• Goodnight, J. A., Mischak, H., Kolch, W. & Mushinski, J. F. Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. Isoform-specific association with microfilaments, Golgi, endoplasmic reticulum, and nuclear and cell membranes. J. Biol. Chem. 270, 9991–10001 (1995).
  CAS PubMed Google Scholar
• Kim, J. et al. Centrosomal PKCβII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 68, 6831–6839 (2008).
  CAS PubMed PubMed Central Google Scholar
• Passalacqua, M., Patrone, M., Sparatore, B., Melloni, E. & Pontremoli, S. Protein kinase C-θ is specifically localized on centrosomes and kinetochores in mitotic cells. Biochem. J. 337, 113–118 (1999).
  CAS PubMed PubMed Central Google Scholar
• Passalacqua, M. et al. Protein kinase C-θ is specifically activated in murine erythroleukaemia cells during mitosis. FEBS Lett. 453, 249–253 (1999).
  CAS PubMed Google Scholar
• Mochly-Rosen, D., Khaner, H. & Lopez, J. Identification of intracellular receptor proteins for activated protein kinase C. Proc. Natl Acad. Sci. USA 88, 3997–4000 (1991). This is the first study to describe RACKs as a means of anchoring activated PKC isozymes to proteins rather than only to lipids.
  CAS PubMed PubMed Central Google Scholar
• Hyatt, S. L., Liao, L., Chapline, C. & Jaken, S. Identification and characterization of α-protein kinase C binding proteins in normal and transformed REF52 cells. Biochemistry 33, 1223–1228 (1994).
  CAS PubMed Google Scholar
• Kheifets, V. & Mochly-Rosen, D. Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. Pharmacol. Res. 55, 467–476 (2007).
  CAS PubMed PubMed Central Google Scholar
• Ron, D. et al. Cloning of an intracellular receptor for protein kinase C: a homolog of the β subunit of G proteins. Proc. Natl Acad. Sci. USA 91, 839–843 (1994).
  CAS PubMed PubMed Central Google Scholar
• Coussens, L., Rhee, L., Parker, P. J. & Ullrich, A. Alternative splicing increases the diversity of the human protein-kinase C family. DNA 6, 389–394 (1987).
  CAS PubMed Google Scholar
• Adwan, T. S., Ohm, A. M., Jones, D. N. M., Humphries, M. J. & Reyland, M. E. Regulated binding of importin-α to protein kinase Cδ in response to apoptotic signals facilitates nuclear import. J. Biol. Chem. 286, 35716–35724 (2011).
  CAS PubMed PubMed Central Google Scholar
• Zinzalla, G. & Thurston, D. E. Targeting protein–protein interactions for therapeutic intervention: a challenge for the future. Future Med. Chem. 1, 65–93 (2009).
  CAS PubMed Google Scholar
• Souroujon, M. C. & Mochly-Rosen, D. Peptide modulators of protein–protein interactions in intracellular signaling. Nature Biotech. 16, 919–924 (1998). This is a review describing how peptide inhibitors of protein–protein interactions can be rationally designed.
  CAS Google Scholar
• Churchill, E. N., Qvit, N. & Mochly-Rosen, D. Rationally designed peptide regulators of protein kinase C. Trends Endocrinol. Metab. 20, 25–33 (2009).
  CAS PubMed Google Scholar
• Qvit, N. & Mochly-Rosen, D. Highly specific modulators of protein kinase C localization: applications to heart failure. Drug Discov. Today Dis. Mech. 7, e87–e93 (2010).
  CAS PubMed PubMed Central Google Scholar
• Prekeris, R., Mayhew, M. W., Cooper, J. B. & Terrian, D. M. Identification and localization of an actin-binding motif that is unique to the epsilon isoform of protein kinase C and participates in the regulation of synaptic function. J. Cell Biol. 132, 77–90 (1996).
  CAS PubMed Google Scholar
• Stebbins, E. G. & Mochly-Rosen, D. Binding specificity for RACK1 resides in the V5 region of βII protein kinase C. J. Biol. Chem. 276, 29644–29650 (2001).
  CAS PubMed Google Scholar
• Ferreira, J. C. et al. Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. J. Mol. Cell. Cardiol. 51, 980–987 (2011).
  CAS PubMed PubMed Central Google Scholar
• Caino, M. C., Lopez-Haber, C., Kim, J., Mochly-Rosen, D. & Kazanietz, M. G. Protein kinase Cɛ is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes. Oncogene 31, 2593–2600 (2012).
  CAS PubMed Google Scholar
• Friedman, E., Hoau Yan, W., Levinson, D., Connell, T. A. & Singh, H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol. Psychiatry 33, 520–525 (1993).
  CAS PubMed Google Scholar
• Hahn, C. G. & Friedman, E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord. 1, 81–86 (1999).
  CAS PubMed Google Scholar
• Podar, K., Raab, M. S., Chauhan, D. & Anderson, K. C. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin. Investig. Drugs 16, 1693–1707 (2007).
  CAS PubMed Google Scholar
• Ali, A. S., Ali, S., El-Rayes, B. F., Philip, P. A. & Sarkar, F. H. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat. Rev. 35, 1–8 (2009).
  CAS PubMed Google Scholar
• Reyland, M. E. Protein kinase C isoforms: multi-functional regulators of cell life and death. Front. Biosci. 14, 2386–2399 (2009).
  CAS PubMed Central Google Scholar
• Bosco, R. et al. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev. Med. Chem. 11, 185–199 (2011).
  CAS PubMed Google Scholar
• Teicher, B. A. Protein kinase C as a therapeutic target. Clin. Cancer Res. 12, 5336–5345 (2006).
  CAS PubMed Google Scholar
• Budas, G. R., Churchill, E. N. & Mochly-Rosen, D. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol. Res. 55, 523–536 (2007).
  CAS PubMed Google Scholar
• Pravdic, D. et al. Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore via protein Kinase C-ɛ-mediated pathway. Anesthesiology 111, 267–274 (2009).
  CAS PubMed Google Scholar
• Philip, P. A. et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J. Natl Cancer Inst. 85, 1812–1818 (1993).
  CAS PubMed Google Scholar
• Propper, D. J. et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br. J. Cancer 78, 1337–1341 (1998).
  CAS PubMed PubMed Central Google Scholar
• Gonzalez, R., Ebbinghaus, S., Henthorn, T. K., Miller, D. & Kraft, A. S. Treatment of patients with metastatic melanoma with bryostatin-1 — a phase II study. Melanoma Res. 9, 599–606 (1999).
  CAS PubMed Google Scholar
• Bedikian, A. Y. et al. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res. 11, 183–188 (2001).
  CAS PubMed Google Scholar
• Brockstein, B. et al. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest. New Drugs 19, 249–254 (2001).
  CAS PubMed Google Scholar
• Varterasian, M. L. et al. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest. New Drugs 19, 245–247 (2001).
  CAS PubMed Google Scholar
• Zonder, J. A. et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin. Cancer Res. 7, 38–42 (2001).
  CAS PubMed Google Scholar
• Pfister, D. G. et al. A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Invest. New Drugs 20, 123–127 (2002).
  CAS PubMed Google Scholar
• Winegarden, J. D. et al. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 39, 191–196 (2003).
  PubMed Google Scholar
• Nezhat, F. et al. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol. Oncol. 93, 144–148 (2004).
  CAS PubMed Google Scholar
• Lam, A. P. et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am. J. Clin. Oncol. 33, 121–124 (2010).
  CAS PubMed PubMed Central Google Scholar
• Haas, N. B. et al. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin. Cancer Res. 9, 109–114 (2003).
  CAS PubMed Google Scholar
• Madhusudan, S. et al. A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. Br. J. Cancer 89, 1418–1422 (2003).
  CAS PubMed PubMed Central Google Scholar
• Ajani, J. A. et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest. New Drugs 24, 353–357 (2006). This is one of several small studies showing a modest partial response rate with bryostatin 1, but with unacceptable toxicity. The study was discontinued owing to grade 3 or grade 4 myalgias in 50% of patients.
  CAS PubMed Google Scholar
• Ku, G. Y. et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother. Pharmacol. 62, 875–880 (2008).
  CAS PubMed Google Scholar
• Cripps, M. C. et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin. Cancer Res. 8, 2188–2192 (2002).
  CAS PubMed Google Scholar
• Tolcher, A. W. et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 8, 2530–2535 (2002).
  CAS PubMed Google Scholar
• Marshall, J. L. et al. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 4, 268–274 (2004).
  CAS PubMed Google Scholar
• Advani, R. et al. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest. New Drugs 23, 467–477 (2005).
  CAS PubMed Google Scholar
• Rao, S. et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase Cα, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann. Oncol. 15, 1413–1418 (2004).
  CAS PubMed Google Scholar
• Lynch, T. J. et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY9000003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc. Am. Soc. Clin. Oncol. 22, 623 (2003).
  Google Scholar
• Paz-Ares, L. et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-α antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 24, 1428–1434 (2006).
  CAS PubMed Google Scholar
• Robertson, M. J. et al. Phase II study of enzastaurin, a protein kinase Cβ inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 25, 1741–1746 (2007).
  CAS PubMed Google Scholar
• Morschhauser, F. et al. A phase II study of enzastaurin, a protein kinase Cβ inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol. 19, 247–253 (2008).
  CAS PubMed Google Scholar
• Oh, Y. et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J. Clin. Oncol. 26, 1135–1141 (2008).
  CAS PubMed Google Scholar
• Glimelius, B. et al. A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Ann. Oncol. 21, 1020–1026 (2010).
  CAS PubMed Google Scholar
• Kreisl, T. N. et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 12, 181–189 (2010).
  CAS PubMed PubMed Central Google Scholar
• Usha, L. et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-β inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol. Oncol. 121, 455–461 (2011).
  CAS PubMed PubMed Central Google Scholar
• Socinski, M. A. et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J. Thorac. Oncol. 5, 1963–1969 (2010).
  PubMed Google Scholar
• Couldwell, W. T. et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin. Cancer Res. 2, 619–622 (1996).
  CAS PubMed Google Scholar
• Bergan, R. C. et al. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 5, 2366–2373 (1999).
  CAS PubMed Google Scholar
• Robins, H. I. et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol. 8, 47–52 (2006).
  CAS PubMed PubMed Central Google Scholar
• Millward, M. J. et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br. J. Cancer 95, 829–834 (2006).
  CAS PubMed PubMed Central Google Scholar
• Fischer, T. et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J. Clin. Oncol. 28, 4339–4345 (2010).
  CAS PubMed PubMed Central Google Scholar
• Rini, B. I. et al. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer 101, 90–95 (2004).
  CAS PubMed Google Scholar
• Welch, S. et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol. Oncol. 106, 305–310 (2007).
  CAS PubMed Google Scholar
• Packer, M. et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J. Am. Coll. Cardiol. 22, 65–72 (1993).
  CAS PubMed Google Scholar
• DeMets, D. L. & Califf, R. M. Lessons learned from recent cardiovascular clinical trials: part II. Circulation 106, 880–886 (2002).
  PubMed Google Scholar
• Aiello, L. P. et al. Oral protein kinase Cβ inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase Cβ inhibitor-diabetic retinopathy study and the protein kinase Cβ inhibitor-diabetic retinopathy study 2. Retina 31, 2084–2094 (2011).
  CAS PubMed Google Scholar
• Ladage, D. et al. Inhibition of PKC α/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ. Res. 109, 1396–1400 (2011).
  CAS PubMed PubMed Central Google Scholar
• Churchill, E. N. & Mochly-Rosen, D. The roles of PKCδ and ɛ isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Biochem. Soc. Trans. 35, 1040–1042 (2007).
  CAS PubMed Google Scholar
• Julier, K. et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 98, 1315–1327 (2003).
  CAS PubMed Google Scholar
• Guarracino, F. et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J. Cardiothorac. Vasc. Anesth. 20, 477–483 (2006).
  CAS PubMed Google Scholar
• Lee, M. C. et al. Isoflurane preconditioning-induced cardio-protection in patients undergoing coronary artery bypass grafting. Eur. J. Anaesthesiol. 23, 841–847 (2006).
  CAS PubMed Google Scholar
• Tritapepe, L. et al. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur. J. Anaesthesiol. 24, 323–331 (2007).
  CAS PubMed Google Scholar
• De Hert, S. et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 64, 953–960 (2009). In this randomized study of 414 patients undergoing CABG, those receiving volatile anaesthetics had reduced 1-year mortality compared to those receiving total intravenous anaesthesia.
  CAS PubMed Google Scholar
• Mentzer, R. M. Jr. et al. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann. Surg. 229, 643–649; discussion 649–650 (1999).
  PubMed PubMed Central Google Scholar
• Belhomme, D. et al. Is adenosine preconditioning truly cardioprotective in coronary artery bypass surgery? Ann. Thorac. Surg. 70, 590–594 (2000).
  CAS PubMed Google Scholar
• Jin, Z. et al. The myocardial protective effects of adenosine pretreatment in children undergoing cardiac surgery: a randomized controlled clinical trial. Eur. J. Cardiothorac. Surg. 39, e90–e96 (2011).
  PubMed Google Scholar
• Mangano, D. T., Miao, Y., Tudor, I. C. & Dietzel, C. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J. Am. Coll. Cardiol. 48, 206–214 (2006).
  PubMed Google Scholar
• Newman, M. F. et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA 308, 157–164 (2012). This large, randomized study comparing the effect of acadesine versus placebo on the composite end point of mortality, nonfatal stroke and severe left ventricular dysfunction in patients undergoing CABG was stopped prematurely for futility.
  CAS PubMed Google Scholar
• Ross, A. M., Gibbons, R. J., Stone, G. W., Kloner, R. A. & Alexander, R. W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol. 45, 1775–1780 (2005). In this randomized trial of 2,118 patients, adenosine failed to reduce the 6-month incidence of heart failure or death compared to placebo.
  CAS PubMed Google Scholar
• Bates, E. et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117, 886–896 (2008).
  PubMed Google Scholar
• Lincoff, A. M. Selective inhibition of delta protein kinase C to reduce infarct size after primary percutaneous intervention for acute myocardial infarction: the PROTECTION-AMI Phase 2b clinical trial. theheart.org website[online], (2011).
• PKC–DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase Cβ Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54, 2188–2197 (2005).
• Aiello, L. P. et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113, 2221–2230 (2006).
  PubMed Google Scholar
• Sheetz, M. J. et al. Effect of ruboxistaurin (RBX) on visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina 31, 1053–1059 (2011). In this long-term study, patients with moderate to severe nonproliferative diabetic retinopathy who received ruboxistaurin for 5 years versus 2 years had a much lower incidence of SMVL (8% versus 26%).
  CAS PubMed Google Scholar
• PKC–DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. 125, 318–324 (2007).
• Campochiaro, P. A. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci. 45, 922–931 (2004).
  PubMed Google Scholar
• Tuttle, K. R. et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28, 2686–2690 (2005).
  CAS PubMed Google Scholar
• Tuttle, K. R., McGill, J. B., Haney, D. J., Lin, T. E. & Anderson, P. W. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin. J. Am. Soc. Nephrol. 2, 631–636 (2007).
  CAS PubMed Google Scholar
• Vinik, A. I. et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase Cβ-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin. Ther. 27, 1164–1180 (2005).
  CAS PubMed Google Scholar
• Casellini, C. M. et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-β inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 30, 896–902 (2007).
  CAS PubMed Google Scholar
• Bebchuk, J. M. et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 57, 95–97 (2000).
  CAS PubMed Google Scholar
• Zarate, C. A. Jr. et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 9, 561–570 (2007).
  CAS PubMed Google Scholar
• Yildiz, A., Guleryuz, S., Ankerst, D. P., Ongur, D. & Renshaw, P. F. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry 65, 255–263 (2008). This study showed that inpatients with acute mania who received tamoxifen rather than placebo had significant improvement in their Young Mania Rating Scale.
  CAS PubMed Google Scholar
• Amrollahi, Z. et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J. Affect Disord. 129, 327–331 (2011).
  CAS PubMed Google Scholar
• Budde, K. et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am. J. Transplant. 10, 571–581 (2010).
  CAS PubMed Google Scholar
• Friman, S. et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am. J. Transplant. 11, 1444–1455 (2011). In this study, individuals randomized to an immunosuppressive regimen containing sotrastaurin instead of tacrolimus had a much higher incidence of acute graft rejection.
  CAS PubMed Google Scholar
• Begely, C. G. & Ellis, L. M. Raise standards for preclinical cancer reseach. Nature 483, 531–533 (2012). This is a good commentary about the challenge of translating preclinical data to successful clinical trials.
  Google Scholar
• Davis, M. I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nature Biotech. 29, 1046–1051 (2011).
  CAS Google Scholar
• Saxena, C., Zhen, E., Higgs, R. E. & Hale, J. E. An immuno-chemo-proteomics method for drug target deconvolution. J. Proteome Res. 7, 3490–3497 (2008).
  CAS PubMed Google Scholar
• Harper, M. T. & Poole, A. W. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J. Thromb. Haemost. 8, 454–462 (2010).
  CAS PubMed Google Scholar
• Duquesnes, N., Lezoualc'h, F. & Crozatier, B. PKC-delta and PKC-epsilon: foes of the same family or strangers? J. Mol. Cell. Cardiol. 51, 665–673 (2011).
  CAS PubMed Google Scholar
• Yang, X., Cohen, M. V. & Downey, J. M. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc. Drugs Ther. 24, 225–234 (2010).
  PubMed PubMed Central Google Scholar
• Chen, C. H. et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321, 1493–1495 (2008).
  CAS PubMed PubMed Central Google Scholar
• Ikeno, F., Inagaki, K., Rezaee, M. & Mochly-Rosen, D. Impaired perfusion after myocardial infarction is due to reperfusion-induced δPKC-mediated myocardial damage. Cardiovasc. Res. 73, 699–709 (2007).
  CAS PubMed Google Scholar
• Ferreira, J. C., Mochly-Rosen, D. & Boutjdir, M. Regulation of cardiac excitability by protein kinase C isozymes. Front. Biosci. 4, 532–546 (2012).
  Google Scholar
• Inagaki, K., Koyanagi, T., Berry, N. C., Sun, L. & Mochly-Rosen, D. Pharmacological inhibition of ɛ-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension 51, 1565–1569 (2008).
  CAS PubMed Google Scholar
• Braz, J. C. et al. PKC-α regulates cardiac contractility and propensity toward heart failure. Nature Med. 10, 248–254 (2004).
  CAS PubMed Google Scholar
• Braun, M. U. & Mochly-Rosen, D. Opposing effects of δ- and ζ-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors. J. Mol. Cell. Cardiol. 35, 895–903 (2003).
  CAS PubMed Google Scholar
• Liu, Q. & Molkentin, J. D. Protein kinase Cα as a heart failure therapeutic target. J. Mol. Cell. Cardiol. 51, 474–478 (2011).
  CAS PubMed Google Scholar
• Hoyt, R. E. & Bowling, L. S. Reducing readmissions for congestive heart failure. Am. Fam. Physician 63, 1593–1598 (2001).
  CAS PubMed Google Scholar
• Simonis, G. et al. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol. Cell. Biochem. 305, 103–111 (2007).
  CAS PubMed Google Scholar
• Bowman, J. C. et al. Expression of protein kinase Cβ in the heart causes hypertrophy in adult mice and sudden death in neonates. J. Clin. Invest. 100, 2189–2195 (1997).
  CAS PubMed PubMed Central Google Scholar
• Hambleton, M. et al. Pharmacological- and gene therapy-based inhibition of protein kinase Cα/β enhances cardiac contractility and attenuates heart failure. Circulation 114, 574–582 (2006).
  CAS PubMed PubMed Central Google Scholar
• Huang, L. et al. Increased contractility and altered Ca2+ transients of mouse heart myocytes conditionally expressing PKCβ. Am. J. Physiol. Cell Physiol. 280, C1114–C1120 (2001).
  CAS PubMed Google Scholar
• Roman, B. B., Geenen, D. L., Leitges, M. & Buttrick, P. M. PKC-β is not necessary for cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 280, H2264–H2270 (2001).
  CAS PubMed Google Scholar
• Takeishi, Y. et al. In vivo phosphorylation of cardiac troponin I by protein kinase Cβ2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts. J. Clin. Invest. 102, 72–78 (1998).
  CAS PubMed PubMed Central Google Scholar
• Ferreira, J. C., Boer, B. N., Grinberg, M., Brum, P. C. & Mochly-Rosen, D. Protein quality control disruption by PKCβII in heart failure; rescue by the selective PKCβII inhibitor, βIIV5-3. PLoS ONE 7, e33175 (2012).
  CAS PubMed PubMed Central Google Scholar
• Connelly, K. A. et al. Inhibition of protein kinase C-β by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ. Heart Fail. 2, 129–137 (2009).
  CAS PubMed Google Scholar
• Ding, R. Q., Tsao, J., Chai, H., Mochly-Rosen, D. & Zhou, W. Therapeutic potential for protein kinase C inhibitor in vascular restenosis. J. Cardiovasc. Pharmacol. Ther. 16, 160–167 (2011).
  CAS PubMed Google Scholar
• Deuse, T. et al. Sustained inhibition of epsilon protein kinase C inhibits vascular restenosis after balloon injury and stenting. Circulation 122, S170–S178 (2010).
  CAS PubMed Google Scholar
• Griner, E. M. & Kazanietz, M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nature Rev. Cancer 7, 281–294 (2007).
  CAS Google Scholar
• Blumberg, P. M., Delclos, K. B., Dunphy, W. G. & Jaken, S. Specific binding of phorbol ester tumor promoters to mouse tissues and cultured cells. Carcinog. Compr. Surv. 7, 519–535 (1982).
  CAS PubMed Google Scholar
• Kheifets, V., Bright, R., Inagaki, K., Schechtman, D. & Mochly-Rosen, D. Protein kinase Cδ (δPKC)-annexin V interaction: a required step in δPKC translocation and function. J. Biol. Chem. 281, 23218–23226 (2006).
  CAS PubMed Google Scholar
• Toker, A. et al. Multiple isoforms of a protein kinase C inhibitor (KCIP-1/14-3-3) from sheep brain — amino acid sequence of phosphorylated forms. Eur. J. Biochem. 206, 453–461 (1992).
  CAS PubMed Google Scholar
• Gold, M. G. et al. Architecture and dynamics of an A-kinase anchoring protein 79 (AKAP79) signaling complex. Proc. Natl Acad. Sci. USA 108, 6426–6431 (2011).
  CAS PubMed PubMed Central Google Scholar
• Klauck, T. M. et al. Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Science 271, 1589–1592 (1996).
  CAS PubMed Google Scholar
• Chapline, C. et al. A major, transformation-sensitive PKC-binding protein is also a PKC substrate involved in cytoskeletal remodeling. J. Biol. Chem. 273, 19482–19489 (1998).
  CAS PubMed Google Scholar
• Mochly-Rosen, D., Khaner, H., Lopez, J. & Smith, B. L. Intracellular receptors for activated protein kinase C. Identification of a binding site for the enzyme. J. Biol. Chem. 266, 14866–14868 (1991). This paper describes the first rationally designed peptide inhibitor of PKC localization.
  CAS PubMed Google Scholar
• Ron, D., Luo, J. & Mochly-Rosen, D. C2 region-derived peptides inhibit translocation and function of β protein kinase C in vivo. J. Biol. Chem. 270, 24180–24187 (1995).
  CAS PubMed Google Scholar
• House, C. & Kemp, B. E. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 238, 1726–1728 (1987). This is the first description of a peptide inhibitor of PKC that acts as a competitive inhibitor of the substrate phosphorylation site.
  CAS PubMed Google Scholar
• Ron, D. & Mochly-Rosen, D. An autoregulatory region in protein kinase C: the pseudoanchoring site. Proc. Natl Acad. Sci. USA 92, 492–496 (1995).
  CAS PubMed PubMed Central Google Scholar
• Dorn, G. W. et al. Sustained in vivo cardiac protection by a rationally designed peptide that causes ɛ protein kinase C translocation. Proc. Natl Acad. Sci. USA 96, 12798–12803 (1999).
  CAS PubMed PubMed Central Google Scholar
• Inagaki, K. et al. Inhibition of δ-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 108, 2304–2307 (2003).
  CAS PubMed Google Scholar
• Armstrong, J. S. & Whiteman, M. Measurement of reactive oxygen species in cells and mitochondria. Methods Cell Biol. 80, 355–377 (2007).
  CAS PubMed Google Scholar
• Murriel, C. L., Churchill, E., Inagaki, K., Szweda, L. I. & Mochly-Rosen, D. Protein kinase Cδ activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J. Biol. Chem. 279, 47985–47991 (2004).
  CAS PubMed Google Scholar
• Konopatskaya, O. & Poole, A. W. Protein kinase Cα: disease regulator and therapeutic target. Trends Pharmacol. Sci. 31, 8–14 (2010).
  CAS PubMed PubMed Central Google Scholar
• Gorin, M. A. & Pan, Q. Protein kinase Cɛ: an oncogene and emerging tumor biomarker. Mol. Cancer 8, 9 (2009).
  PubMed PubMed Central Google Scholar
• Lee, S. K. et al. Apurinic/apyrimidinic endonuclease 1 inhibits protein kinase C-mediated p66shc phosphorylation and vasoconstriction. Cardiovasc. Res. 91, 502–509 (2011).
  CAS PubMed PubMed Central Google Scholar
• Standaert, M. L. et al. Effects of knockout of the protein kinase Cβ gene on glucose transport and glucose homeostasis. Endocrinology 140, 4470–4477 (1999).
  CAS PubMed Google Scholar
• Chen, C. & Mochly-Rosen, D. Opposing effects of δ and ɛPKC in ethanol-induced cardioprotection. J. Mol. Cell. Cardiol. 33, 581–585 (2001).
  CAS PubMed Google Scholar
• Mochly-Rosen, D. et al. Cardiotrophic effects of protein kinase Cɛ: analysis by in vivo modulation of PKCɛ translocation. Circ. Res. 86, 1173–1179 (2000).
  CAS PubMed Google Scholar
• Koide, Y. et al. Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats. Hypertens. Res. 26, 421–426 (2003).
  CAS PubMed Google Scholar
• Limnander, A. et al. STIM1, PKC-δ and RasGRP set a threshold for proapoptotic Erk signaling during B cell development. Nature Immunol. 12, 425–433 (2011).
  CAS Google Scholar
• Kilpatrick, L. E. et al. Protection against sepsis-induced lung injury by selective inhibition of protein kinase C-δ (δ-PKC). J. Leukoc. Biol. 89, 3–10 (2011).
  CAS PubMed PubMed Central Google Scholar
• Boschelli, D. H. Small molecule inhibitors of PKCθ as potential antiinflammatory therapeutics. Curr. Top. Med. Chem. 9, 640–654 (2009).
  CAS PubMed Google Scholar
• Bright, R., Steinberg, G. K. & Mochly-Rosen, D. δPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. Brain Res. 1144, 146–155 (2007).
  CAS PubMed PubMed Central Google Scholar
• Chou, W. H. & Messing, R. O. Hypertensive encephalopathy and the blood–brain barrier: is δPKC a gatekeeper? J. Clin. Invest. 118, 17–20 (2008).
  CAS PubMed Google Scholar
• Qi, X., Disatnik, M. H., Shen, N., Sobel, R. A. & Mochly-Rosen, D. Aberrant mitochondrial fission in neurons induced by protein kinase Cδ under oxidative stress conditions in vivo. Mol. Biol. Cell 22, 256–265 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bright, R., Sun, G. H., Yenari, M. A., Steinberg, G. K. & Mochly-Rosen, D. ɛPKC confers acute tolerance to cerebral ischemic reperfusion injury. Neurosci. Lett. 441, 120–124 (2008).
  CAS PubMed PubMed Central Google Scholar
• Langlois, A. et al. Crucial implication of protein kinase C (PKC)-δ, PKC-ζ, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils. J. Leukoc. Biol. 85, 656–663 (2009).
  CAS PubMed Google Scholar
• Kanthasamy, A. G. et al. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase Cδ (PKCδ) protects against dopaminergic neuronal degeneration in Parkinson's disease models. Free Radic. Biol. Med. 41, 1578–1589 (2006).
  CAS PubMed Google Scholar
• Sawada, M., Imamura, K. & Nagatsu, T. Role of cytokines in inflammatory process in Parkinson's disease. J. Neural Transm. Suppl. 2006, 373–381 (2006).
  Google Scholar
• Defauw, J. M. et al. Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J. Med. Chem. 39, 5215–5227 (1996).
  CAS PubMed Google Scholar
• Swannie, H. C. & Kaye, S. B. Protein kinase C inhibitors. Curr. Oncol. Rep. 4, 37–46 (2002).
  PubMed Google Scholar
• Lee, K.-W. et al. Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer. Cancer Res. 68, 1916–1926 (2008).
  CAS PubMed Google Scholar
• Gray, M. O., Karliner, J. S. & Mochly-Rosen, D. A selective ɛ-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J. Biol. Chem. 272, 30945–30951 (1997).
  CAS PubMed Google Scholar
• Lahn, M., Sundell, K. & Moore, S. Targeting protein kinase C-α (PKC-α) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen. Ann. NY Acad. Sci. 1002, 263–270 (2003).
  CAS PubMed Google Scholar
• Goekjian, P. G. & Jirousek, M. R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs 10, 2117–2140 (2001).
  CAS PubMed Google Scholar
• Tamaoki, T. Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Methods Enzymol. 201, 340–347 (1991).
  CAS PubMed Google Scholar
• Kraft, A. S., Smith, J. B. & Berkow, R. L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc. Natl Acad. Sci. USA 83, 1334–1338 (1986).
  CAS PubMed PubMed Central Google Scholar
• Schwarze, S. R., Ho, A., Vocero-Akbani, A. & Dowdy, S. F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569–1572 (1999).
  CAS PubMed Google Scholar
• Qi, X., Inagaki, K., Sobel, R. A. & Mochly-Rosen, D. Sustained pharmacological inhibition of δPKC protects against hypertensive encephalopathy through prevention of blood–brain barrier breakdown in rats. J. Clin. Invest. 118, 173–182 (2008).
  CAS PubMed Google Scholar
• Kim, J., Thorne, S. H., Sun, L., Huang, B. & Mochly-Rosen, D. Sustained inhibition of PKCα reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 30, 323–333 (2011).
  CAS PubMed Google Scholar
• Inagaki, K., Begley, R., Ikeno, F. & Mochly-Rosen, D. Cardioprotection by ɛ-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an ɛ-protein kinase C-activating peptide. Circulation 111, 44–50 (2005).
  CAS PubMed Google Scholar
• Drew, B. G. & Kingwell, B. A. Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin. Pharmacother. 9, 2137–2144 (2008).
  CAS PubMed Google Scholar
• Zhao, B. et al. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 277, 46609–46615 (2002).
  CAS PubMed Google Scholar